Cargando…
Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022
PURPOSE: Assessment of the US FDA-issued WLs content is an educational tool that can be used in the continuous training program of community pharmacists in compounding pharmacies. The study was designed to critically assess FDA warning letters (WLs) issued to compounding pharmacies in 2017–2022 for...
Autor principal: | Dmour, Isra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666930/ https://www.ncbi.nlm.nih.gov/pubmed/36407089 http://dx.doi.org/10.1007/s12247-022-09692-4 |
Ejemplares similares
-
An analysis of the warning letters issued by the FDA to
pharmaceutical manufacturers regarding misleading health outcomes
claims
por: Chatterjee, Satabdi, et al.
Publicado: (2012) -
FDA Warning Letters: A Retrospective Analysis of Letters Issued to Pharmaceutical Companies from 2010–2020
por: Rathore, Anurag S., et al.
Publicado: (2022) -
Content Analysis of 2012-2019 FDA Warning Letters and Notices of Violations using the Economic, Clinical, and Humanistic Outcomes (ECHO) Model
por: Mohite, Namosha, et al.
Publicado: (2021) -
An FDA Analysis of Inspected Entities After Receiving Official Action Indicated Letters for Good Clinical Practice Violations
por: Jung, Miah, et al.
Publicado: (2021) -
Unicorn Poo and Blessed Waters: COVID-19 Quackery and FDA Warning Letters
por: Bramstedt, Katrina A.
Publicado: (2020)